This episode of "This Week in Virology" (TWiV 519) delves into the burgeoning and controversial hypothesis linking Herpes Simplex Virus Type 1 (HSV-1) to Alzheimer's Disease (AD). The discussion covers the basic biology of HSV-1, its latency in neurons, and rare cases of herpes encephalitis. The hosts analyze a clinical trial investigating the use of anti-herpetic antivirals for AD and a large-scale Taiwanese cohort study suggesting a reduced risk of dementia in HSV-1 infected patients treated with antivirals. A significant portion of the conversation explores the "bioflocculate hypothesis," where amyloid-beta, a hallmark of AD, is posited as an innate antimicrobial peptide that encapsulates virus particles. The episode examines a research paper demonstrating that HSV-1 infection rapidly seeds amyloid-beta fibrillization in vitro and in vivo. The panel debates whether HSV-1 is a direct cause or a consequence of inflammation in the brain, the nature of AD subtypes, and the potential efficacy of antivirals against abortive or low-level viral reactivation, ultimately suggesting a vaccine might be a more promising long-term solution.
Summarizing TWiV 519: Fishing for viruses in senile
0:00 - Introduction to HSV-1 and Alzheimer's Disease (AD): The hosts introduce the podcast's main topic: the potential connection between Herpes Simplex Virus Type 1 (HSV-1) and Alzheimer's Disease (AD), a subject that has been gaining recent media attention.
6:14 - HSV-1 Basic Biology: HSV-1 is described as a large, enveloped double-stranded DNA virus, commonly causing oral lesions. It becomes latent in trigeminal ganglia (peripheral neurons) and can reactivate under stress, leading to cold sores. Notably, 47.8% of people in the US are infected with HSV-1 by age 49.
11:13 - Herpes Encephalitis: A rare but severe complication where HSV-1 travels to the brain, causing encephalitis, particularly dangerous in neonates. This highlights the potential for HSV-1 to enter the central nervous system (CNS).
12:28 - Valacyclovir Clinical Trial for AD: An ongoing clinical trial at Columbia University is introduced, administering the anti-herpes antiviral valacyclovir to AD patients for 78 weeks, based on the hypothesis that HSV-1 in the brain contributes to AD.
13:27 - HSV-1 Presence in the Brain: Herpes virologist David Knipe confirms that HSV-1 DNA sequences and transcripts are found in the CNS of many individuals, suggesting "abortive reactivation" (low-level viral activity without full replication) that might cause inflammation and neurodegeneration in AD.
15:50 - Review Article and Genetic Predisposition: A review article implicates HSV-1 in AD, particularly in individuals carrying the apolipoprotein E epsilon 4 isoform, which is associated with more frequent HSV-1 reactivation and a higher risk of AD.
18:37 - Amyloid-Beta and Tau Protein in AD: The discussion touches on the debate surrounding amyloid-beta plaques and hyperphosphorylated tau protein tangles in AD. The "bioflocculate hypothesis" suggests amyloid-beta acts as an innate antimicrobial peptide, aggregating to encapsulate pathogens.
21:11 - AD as "Type 3 Diabetes": Parallels between AD and diabetes are drawn, suggesting AD could be considered a "Type 3 diabetes" due to changes in insulin responsiveness in brain cells and a shared link to inflammation and oxidative stress.
25:09 - Taiwan Cohort Study Findings: A large-scale Taiwanese health database study found that individuals with HSV-1 infections had a 2.56-fold greater risk of developing senile dementia. Crucially, a subgroup treated with anti-herpetic medications showed a tenfold decrease in dementia incidence compared to untreated individuals.
29:09 - Interpreting the Taiwan Data: The hosts express intrigue but also caution regarding the Taiwan study, emphasizing that it shows association, not causation, and may be influenced by confounding factors. They question the mechanism, as antivirals primarily target active viral replication, not latency.
41:19 - Inflammation as a Unifying Factor: The panel hypothesizes that inflammation could be a central, unifying factor in AD pathogenesis, potentially triggered by genetic predispositions, diet, or viral infections like HSV-1. It's debated whether HSV-1 is a cause of this inflammation or a consequence.
44:11 - Efficacy of Antivirals for Latent Virus: The discussion critically examines whether antivirals, designed for acute infections, can effectively impact latent or abortive HSV-1 in the brain to prevent AD, and if continuous treatment would be required.
50:01 - Vaccine as a Better Solution: A vaccine against HSV-1 is proposed as a more logical and potentially effective long-term strategy to reduce AD incidence if the viral link is indeed causal, by preventing initial infection.
54:36 - Amyloid-Beta as Antiviral (Neuron Paper): A detailed review of a Neuron paper highlights experiments in cell culture and mouse models showing that AD-associated amyloid-beta rapidly aggregates around herpesviruses, encapsulating them to protect against brain infection.
1:00:08 - Infection Induces Fibril Deposition: The study found that HSV-1 infection induces the deposition of amyloid-beta fibrils, which co-localize with viral glycoproteins on the virus surface, forming a network to entrap the virus within 15 minutes.
1:02:27 - Brain's Unique Immune Responses: The "immune privileged" nature of the brain is discussed, noting that while it has barriers, it also possesses unique and active immune responses, including the production of antimicrobial peptides like amyloid-beta.
1:05:28 - Listener Emails: Several listener emails are read, covering topics such as personal impact of TWiV, a critique of a glyphosate paper, the evolutionary aspects of restriction factors, and a tribute to a pioneering Portuguese virologist.
1:17:24 - Science Picks: The episode concludes with various science-related recommendations from the hosts and a listener, including the board game "Pandemic," the "Shortwave Radio Audio Archive," an interactive map of James Cook's voyage, "The Scientist" magazine's Instagram, "State of the World's Fungi 2018," and a New York Times article on philosopher Bruno Latour.